Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: A multicentre study

Annals of Hematology

Volumn 91, Issue 12, 2012, Pages 1945-1952

  Blommestein, H M ^a   Verelst, S G R ^b   Huijgens, P C ^c,e   Blijlevens, N M A ^d   Cornelissen, J J ^b,f   Uyl De Groot, C A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Haemato Oncology Foundation for Adults in the Netherlands (HOVON)   (Netherlands)

^f Stem Cell Transplantation Working Group HOVON   (Netherlands)

Author keywords

Allogeneic; Autologous; Cost; Haematology; Reimbursement; Stem cell transplantation

Indexed keywords

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD DONOR; BUDGET; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SIBLING; UMBILICAL CORD BLOOD; UNIVERSITY HOSPITAL; UNRELATED DONORS;

ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; COSTS AND COST ANALYSIS; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LABORATORIES, HOSPITAL; LENGTH OF STAY; MALE; MIDDLE AGED; NETHERLANDS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84871026987     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1530-2     Document Type: Article

References (16)

1. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al (2010) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 45(2):219-234
2. Lodewyck T, Cornelissen JJ (2008) Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. Blood Rev 22(6):293-302
3. Lodewyck T, Oudshoorn M, van der Holt B, Petersen E, Spierings E, Von dem Borne PA et al (2011) Predictive impact of allelematching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia. Leukemia 25(10):1548-1554
4. HOVON-the Haemato Oncology Foundation for Adults in the Netherlands-HOVON Stem Cell Working Group and Transplantation Registry, part of the international registry of the European Group for Blood and Marrow transplantation (EBMT). 2012;2012
5. van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA (2001) Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. Eur J Cancer 37(14):1781-1789
6. van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, van der Holt B, Lokhorst HM et al (2004) A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study. Eur J Cancer 40(8):1159-1169
7. Mishra V, Vaaler S, Brinch L (2001) A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures. Bone Marrow Transplant 28(12):1111-1116
8. Mishra V, Andresen S, Brinch L, Kvaloy S, Ernst P, Lonset MK et al (2005) Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 35(12):1149-1153
9. The Dutch Healthcare Authority DRG tariffs. [In Dutch: DBCtariefapplicatie.] http://dbctarieven.nza.nl/Nzatarieven/top.do31-12- 2009;2010(2/12).
10. Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, Uyl-de Groot CA (2012) Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther (In Press)
11. Tan SS, Van Gils CW, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA (2010) The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health 13(6):712-719
12. Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ (2009) Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 15(5):564-573
13. Esperou H, Brunot A, Roudot-Thoraval F, Buzyn A, Dhedin N, Rio B et al (2004) Predicting the costs of allogeneic sibling stemcell transplantation: results from a prospective, multicenter, French study. Transplantation 77(12):1854-1858
14. Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP et al (2008) Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 14(2):197-207
15. Lee SJ, Klar N, Weeks JC, Antin JH (2000) Predicting costs of stem-cell transplantation. J Clin Oncol 18(1):64-71
16. Dutch Healthcare Authority, Policy budgeting teaching hospitals, CI- 1125. [In Dutch: Nederlandse Zorgautoriteit Beleidsregel CI-1125 Functiegerichte budgettering academische ziekenhuizen 2010]. http://www.nza.nl/137706/145406/ CI-1125.pdf Accessed: May 2012